Substances · Benzodiazepines and thienodiazepines
Norflurazepam
- Preferred name
- Norflurazepam
- IUPAC name
- 7-chloro-5-(2-fluorophenyl)-1,3-dihydro-1,4-benzodiazepin-2-one
- Parent CAS number (reference)
- 2886-65-9
- Molecular formula
- C15H10ClFN2O
- Molecular weight
- 288.7 g/mol
- InChIKey
- UVCOILFBWYKHHB-UHFFFAOYSA-N
- PubChem
- CID 4540
- Source
- PubChem
- Verified synonyms & catalog abbreviations
-
N-Desalkylflurazepam Ro 5-3367
Matching Listings in This Store's Catalog
Verified Neurochemical & Toxicological Intelligence
Norflurazepam
Receptor Telemetry & Mechanism of Action
N-Desalkylflurazepam, the principal long-lived active metabolite of flurazepam, binding broadly across synaptic GABA-A benzodiazepine sites.
Biotransformation & Active Metabolites
Glucuronidated slowly with a documented human elimination half-life of ~40–100 hours.
Temporal Pharmacokinetics
Long-Acting Myorelaxant & Anxiolytic GABA-A PAM — Gentle per-tablet scale (1 tablet = 1 mg; common literature range 5–10 mg) with warm myorelaxation and a smooth multi-day tail comparable to diazepam/diclazepam.
- Onset 30–90 min
- Peak Window 2–4 h
- Total Window 10–18 h
- Residual / Half-Life 24–60 h residual (T1/2 40–100 h)
Gentle per-tablet scale (1 tablet = 1 mg; common literature range 5–10 mg) with warm myorelaxation and a smooth multi-day tail comparable to diazepam/diclazepam.
Quantitative Response Spectrum (Published Literature)
Third-person observational & toxicological brackets reported in scientific and harm-reduction literature — reference telemetry only, never consumption advice.
2 mg
Subtle threshold receptor activity (Long-Acting Myorelaxant & Anxiolytic GABA-A PAM).
Minimal baseline autonomic shift.
2–5 mg
Mild, clear-headed expression of primary class profile.
Light somatic modulation.
5–10 mg
Full characteristic neurochemical and perceptual profile documented in literature.
Moderate somatic relaxation, ataxia, or autonomic tone depending on class.
10–15 mg
Pronounced intensity, cognitive/motor impairment, or deep immersion.
Marked somatic load and heightened adverse-event sensitivity.
20+ mg
Amnesia, blackout, acute dysphoria, confusion, or anesthetic dissociation.
High toxicity zone: severe motor loss, cardiovascular strain, or respiratory hazard.
Interaction Matrix & Critical Contraindications
Critical Hazard — Never Combine
Synergistic brainstem respiratory depression causing unconsciousness and fatal respiratory arrest.
Extreme CNS depression, complete anterograde amnesia, loss of airway reflexes, and fatal aspiration.
Elevated Hazard — Avoid
Unpredictable sedation, severe motor ataxia, blackout, and emesis aspiration hazard.
Caution / Receptor Attenuation
CYP3A4 inhibitors prolong plasma half-life; stimulants mask sedation until they wear off.
Structural Isomer & Sibling Comparison
Gentle per-tablet scale (1 tablet = 1 mg; common literature range 5–10 mg) with warm myorelaxation and a smooth multi-day tail comparable to diazepam/diclazepam.
Physicochemical Stability & Storage
Form: Precision-pressed 1 mg analytical tablets (1 tablet = 1 mg). · Parent molecule soluble in ethanol, propylene glycol, and DMSO; sparingly soluble in water.
Store sealed in a cool, dry, light-protected container away from humidity.
Cross-Tolerance & Dependence Profile
Complete cross-tolerance across all GABA-A benzodiazepines/thienodiazepines. Rapid physical dependence develops with continuous daily exposure; abrupt cessation after prolonged intake can trigger life-threatening rebound seizures and delirium.
Chemical Architecture & Structural Profile
Norflurazepam (7-chloro-5-(2-fluorophenyl)-1,3-dihydro-1,4-benzodiazepin-2-one) is a reference compound belonging to the Benzodiazepines and thienodiazepines class, characterized by the molecular formula C15H10ClFN2O and a molar mass of 288.7 g/mol. The parent molecule is indexed under CAS registry number 2886-65-9 and in the NCBI PubChem database as CID 4540 (Standard InChIKey: UVCOILFBWYKHHB-UHFFFAOYSA-N).
Citations
- PubChem — PubChem (2026-11-12)
Reference Toxicology & Safety Profile
In documented chemical and harm-reduction literature (PubChem / PsychonautWiki, CC BY 4.0), Norflurazepam is indexed within the Benzodiazepines and thienodiazepines structural group. Triazolo/thienodiazepine reference compound; carries a high risk of synergistic respiratory depression if combined with opioids, alcohol, or other CNS depressants. Standard laboratory handling precautions—including nitrile gloves, eye protection, and local exhaust ventilation—apply whenever handling the reference material.
Citations
- PubChem — PubChem (2026-11-12)
Analytical Use & Laboratory Notice
This reference sheet provides chemical, analytical, and toxicological provenance only. The material is strictly not for human consumption, diagnostic, or veterinary use. Research-use labelling does not establish legal status in any jurisdiction.
Citations
- EUDA / National Chemical & Controlled Substance Registry (AE) — National Regulatory Authority (AE) (2026-11-12)